Bifogade filer
Modus Therapeutics to present preclinical data on sevuparin in CKD with anemia at EHA2026 in Stockholm
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Stockholm, 13 May 2026 – Modus Therapeutics Holding AB ("Modus" or the "Company") today announced that an abstract describing preclinical research on the therapeutic potential of sevuparin in anemia associated with chronic kidney disease (CKD) has been accepted for poster presentation at the European Hematology Association Congress 2026 (EHA2026) in Stockholm, 11–14 June 2026.
The abstract, titled "Therapeutic potential of sevuparin in chronic kidney disease anaemia: synergistic effects with EPO and molecular insights into renal protection", presents preclinical data that further characterize the mechanism of action of sevuparin in CKD with anemia, including its interaction with the standard treatment erythropoietin (EPO) and molecular observations with potential relevance to renal function. The study has been conducted in collaboration between Modus and researchers at the University of Brescia.Since 2018 this collaboration has contributed to the preclinical and translational work that helps form the biological foundation for Modus' ongoing clinical development of sevuparin.
"We are pleased that our collaborators in Brescia have the opportunity to present this work at EHA2026. The data deepen the understanding of the biology of sevuparin in CKD with anemia and complement the clinical development we are currently advancing in our ongoing Phase IIa study," said John Öhd, CEO of Modus Therapeutics.
Anemia in CKD is markedly aggravated by chronic inflammation and elevated levels of hepcidin, a hormone that controls iron availability for blood formation. Despite the presence of EPO-based therapies, many patients respond inadequately, particularly during active inflammation. Sevuparin acts by lowering hepcidin elevated via both basal iron-regulatory (BMP/SMAD) and inflammatory (IL-6) pathways, which constitutes a mechanism of action that is differentiated from erythropoiesis-stimulating agents (ESAs) and HIF-PH inhibitors, and is being developed as a potential complementary therapy to existing treatments.
Presentation details
- Abstract code: PS2400
- Title: Therapeutic potential of sevuparin in chronic kidney disease anaemia: synergistic effects with EPO and molecular insights into renal protection
- Presenting author: Dr. Michela Asperti, University of Brescia
- Format: Poster presentation
- Session: Poster Session 2, Saturday 13 June 2026, 18:45–19:45 CEST
- Venue: Stockholmsmässan, Stockholm, Sweden
The abstract is published through EHA's official channels and in HemaSphere, the official journal of EHA. The poster will also be made available in the EHA Congress platform from 11 June 2026.